Rapid responses are electronic comments to the editor. They enable our users
to debate issues raised in articles published on bmj.com. A rapid response
is first posted online. If you need the URL (web address) of an individual
response, simply click on the response headline and copy the URL from the
browser window. A proportion of responses will, after editing, be published
online and in the print journal as letters, which are indexed in PubMed.
Rapid responses are not indexed in PubMed and they are not journal articles.
The BMJ reserves the right to remove responses which are being
wilfully misrepresented as published articles or when it is brought to our
attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not
including references and author details. We will no longer post responses
that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
Reduction in funding for neuroscience is most untimely in view of the
rising numbers of people living long enough to suffer dementia and other
neuropathies.
There are solutions waiting for trial which can be of huge assistance to
the NHS and to sufferers whilst at the same time saving money. They won't
see the light of day if funds are cut now.
A good example is the potential treatment of AD with anti-virals
following the work of Matthew Wozniak and Ruth Itzhaki in Manchester.
Trial of this should be a priority.
Another example is the treatment of Parkinson's with a 'tonic' of
food additives and supplements which has resulted in some cases reporting
almost complete regression of symptoms - as if it was a nutrient
deficiency syndrome. Surely worthy of funding in view of the benefits
available. see www.brainhelp.info
Now is not the time for cuts - widen the field of view and fund new
work which will show value for money.
Wozniak MA, Itzhaki RF. (2010) Antiviral agents in Alzheimer's
disease: hope for the future? Therapeutic Advances in Neurological
Disorders 3, 141-52.
Competing interests:
Developer of the Parkinson's Improvement Programme from which I receive no financial gain.
Difficulty in obtaining grants for small and novel trials
Reduction in funding for neuroscience is most untimely in view of the
rising numbers of people living long enough to suffer dementia and other
neuropathies.
There are solutions waiting for trial which can be of huge assistance to
the NHS and to sufferers whilst at the same time saving money. They won't
see the light of day if funds are cut now.
A good example is the potential treatment of AD with anti-virals
following the work of Matthew Wozniak and Ruth Itzhaki in Manchester.
Trial of this should be a priority.
Another example is the treatment of Parkinson's with a 'tonic' of
food additives and supplements which has resulted in some cases reporting
almost complete regression of symptoms - as if it was a nutrient
deficiency syndrome. Surely worthy of funding in view of the benefits
available. see www.brainhelp.info
Now is not the time for cuts - widen the field of view and fund new
work which will show value for money.
Wozniak MA, Itzhaki RF. (2010) Antiviral agents in Alzheimer's
disease: hope for the future? Therapeutic Advances in Neurological
Disorders 3, 141-52.
Competing interests: Developer of the Parkinson's Improvement Programme from which I receive no financial gain.